Log in to save to my catalogue

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer pati...

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer pati...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2520870734

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study

About this item

Full title

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study

Publisher

United States: Elsevier Inc

Journal title

International journal of gynecological cancer, 2021-06, Vol.31 (6), p.875-882

Language

English

Formats

Publication information

Publisher

United States: Elsevier Inc

More information

Scope and Contents

Contents

ObjectiveTo explore the clinical and biological prognostic factors for advanced ovarian cancer patients receiving first-line treatment with carboplatin, paclitaxel, and bevacizumab.MethodsA multicenter, phase IV, single arm trial was performed. Patients with advanced (FIGO (International Federation of Gynecology and Obstetrics) stage IIIB-IV) or re...

Alternative Titles

Full title

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2520870734

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2520870734

Other Identifiers

ISSN

1048-891X

E-ISSN

1525-1438

DOI

10.1136/ijgc-2021-002434

How to access this item